(Q36742405)

16 August 2017

1 reference

title

Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention (English)

1 reference

16 August 2017

0 references

Manju T Beier

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

27

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

399-411

1 reference

Alzheimer Disease in the US Population

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

People with dementia and their relatives: personal experiences of Alzheimer's and of the provision of care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Informal Costs of Dementia Care: Estimates From the National Longitudinal Caregiver Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Recognition and Management of Behavioral Disturbances in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Bingo vs. physical intervention in stimulating short-term cognition in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Occipital atrophy is associated with visual hallucinations in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Relationship between delusions and regional cerebral blood flow in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Medial temporal hypoperfusion and aggression in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Psychotropic drug use and the risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Fall risk index for elderly patients based on number of chronic disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

Atypical Antipsychotics and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.399

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.3.399

1 reference

16 August 2017

1 reference